Table 1.

Summary of trial designs.

	CO40151	IPATunity130, Cohort C	IPATunity170
Design	Phase Ib	Open-label single-arm cohort within phase III	Two-cohort placebo-controlled randomized phase III
Geographic locations	Australia, France, Spain, UK, USA	Europe, North and South America, Asia	Europe, Asia, Australia, North and South America
Taxane backbone	Paclitaxel or nab-paclitaxel	Paclitaxel	Paclitaxel
Comparator arms	None	None	PD-L1–positive cohort: atezolizumab + paclitaxel
			PD-L1–negative/unknown cohort: paclitaxel alone or paclitaxel + ipatasertib
PIK3CA/AKT1/PTEN mutation status	Unselected	Not altered	Unselected
Known BRCA1/2 mutation eligible	Yes	Yes	No (unless ineligible for PARP inhibitor)
Primary endpoint	Confirmed ORR and DoR	PFS	PFS and OS
Secondary efficacy endpoints	PFS, confirmed CBR, OS	Confirmed ORR (RECIST version 1.1), DoR, CBR, OS, 1-year PFS rate, 1-year OS rate	All nonprimary predefined endpoints were exploratory

Abbreviations: CBR, clinical benefit rate (stable disease for ≥24 weeks or confirmed complete/partial response); DoR, duration of response (interval between confirmed complete/partial response and disease progression or death).